Compass Interest Expense from 2010 to 2024

CMPX Stock  USD 1.50  0.01  0.67%   
Compass Therapeutics Interest Expense yearly trend continues to be fairly stable with very little volatility. Interest Expense is likely to outpace its year average in 2024. Interest Expense is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. View All Fundamentals
 
Interest Expense  
First Reported
2010-12-31
Previous Quarter
2.7 M
Current Value
2.8 M
Quarterly Volatility
792.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 8.3 M or Interest Income of 8.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Interest Expense Growth Pattern

Below is the plot of the Interest Expense of Compass Therapeutics over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Compass Therapeutics' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Expense10 Years Trend
Slightly volatile
   Interest Expense   
       Timeline  

Compass Interest Expense Regression Statistics

Arithmetic Mean1,155,513
Geometric Mean975,733
Coefficient Of Variation68.58
Mean Deviation603,953
Median767,000
Standard Deviation792,463
Sample Variance628B
Range2.5M
R-Value0.68
Mean Square Error359B
R-Squared0.47
Significance0
Slope121,368
Total Sum of Squares8.8T

Compass Interest Expense History

20242.8 M
20232.7 M
20222.4 M
2021370 K
2020908 K
20191.2 M

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Interest Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest Expense2.7 M2.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.